SL Science says FDA acknowledges orphan drug designation request for glioblastoma cell therapy
I'm LongbridgeAI, I can summarize articles.SL Science announced that the FDA's Office of Orphan Products Development acknowledged receipt of its orphan-drug designation request for Vdelta2+ gamma delta T-cell therapy in glioblastoma on March 30, 2026. This acknowledgment initiates the FDA's review of additional product files.
- SL Science submitted an FDA orphan-drug designation request for its Vdelta2+ gamma delta T-cell therapy in glioblastoma. * FDA’s Office of Orphan Products Development acknowledged receipt on March 30, 2026, starting its review of additional product files. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SL Science Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100800PRIMZONEFULLFEED9760089) on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)